文献速递炎症性肠病

炎症性肠病肠外表现的全面关联分析

Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease.
PubMed 文献 · Gastroenterology · 2024-03-13

该研究汇集4个队列共12083例欧洲血统炎症性肠病病例,分析肠外表现相关的临床、血清学和遗传因素。多数肠外表现与女性、克罗恩病(尤其结肠病变)及需手术者相关,吸烟除对原发性硬化性胆管炎呈「保护」效应外增加肠外表现风险。主要组织相容性复合体及CPEB4基因位点与多种肠外表现全基因组显著关联,肿瘤坏死因子、JAK-STAT和IL6通路被提示为潜在靶点。

要点

  • 多数肠外表现更常见于女性、克罗恩病(尤其结肠病变)及需手术者。
  • 吸烟增加肠外表现风险,但对原发性硬化性胆管炎呈「保护」效应。
  • 仅2%受试者出现多种肠外表现,且多数共现呈负相关。

核心结论

  • 研究识别了肠外表现的人口学、临床和遗传关联,揭示潜在机制并提示新老药物靶点,是迈向炎症性肠病个体化管理的重要步骤。

研究设计与样本

  • 研究纳入4个队列(Cedars-Sinai医学中心、美国糖尿病与消化及肾脏疾病研究所炎症性肠病遗传学联盟、Sinai Helmsley研究卓越联盟、克罗恩病儿童快速进展风险分层与免疫遗传及微生物标志物队列)的12083例无亲缘关系的欧洲血统炎症性肠病病例,分析肠外表现(强直性脊柱炎包括强直性脊柱炎和骶髂关节炎、原发性硬化性胆管炎、外周关节炎、皮肤和眼部表现)的存在与否。
  • 临床和血清学参数采用混合效应模型的单变量和多变量回归分析,遗传关联采用病例内逻辑回归分析。

主要发现

  • 多数肠外表现更常见于女性(总体肠外表现:P=9.0E-05,OR=1.2,95%CI 1.1-1.4)、克罗恩病(尤其结肠病变部位;P=9.8E-09,OR=1.7,95%CI 1.4-2.0)及需要手术者(克罗恩病和溃疡性结肠炎均如此;P=3.6E-19,OR=1.7,95%CI 1.5-1.9)。
  • 吸烟增加肠外表现风险,但对原发性硬化性胆管炎呈「保护」效应。
  • 观察到多种血清学关联,包括原发性硬化性胆管炎与抗中性粒细胞胞质抗体IgG和IgA、抗酿酒酵母菌抗体及抗鞭毛蛋白,任何肠外表现与抗中性粒细胞胞质抗体IgG和IgA、抗酿酒酵母菌抗体及抗荧光假单胞菌相关序列。
  • 主要组织相容性复合体内全基因组显著关联:强直性脊柱炎和骶髂关节炎(P=1.4E-15,OR=2.5,95%CI 2.0-3.1)、原发性硬化性胆管炎(P=2.7E-10,OR=2.8,95%CI 2.0-3.8)、眼部表现(P=2E-08,OR=3.6,95%CI 2.3-5.6)及总体肠外表现(P=8.4E-09,OR=2.2,95%CI 1.7-2.9);CPEB4与皮肤表现关联(P=2.7E-08,OR=1.5,95%CI 1.3-1.8)。
  • 遗传关联提示肿瘤坏死因子、JAK-STAT和IL6为肠外表现的潜在靶点;与既往报道相反,仅2%受试者有多种肠外表现,且多数共现呈负相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with inflammatory bowel disease (IBD) frequently develop extraintestinal manifestations (EIMs) that contribute substantially to morbidity. We assembled the largest multicohort data set to date to investigate the clinical, serologic, and genetic factors associated with EIM complications in IBD. METHODS: Data were available in 12,083 unrelated European ancestry IBD cases with presence or absence of EIMs (eg, ankylosing spondylitis [ankylosing spondylitis and sacroiliitis], primary sclerosing cholangitis [PSC], peripheral arthritis, and skin and ocular manifestations) across 4 cohorts (Cedars-Sinai Medical Center, National Institute for Diabetes and Digestive and Kidney Diseases IBD Genetics Consortium, Sinai Helmsley Alliance for Research Excellence Consortium, and Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease cohort). Clinical and serologic parameters were analyzed by means of univariable and multivariable regression analyses using a mixed-effects model. Within-case logistic regression was performed to assess genetic associations. RESULTS: Most EIMs occurred more commonly in female subjects (overall EIM: P = 9.0E-05, odds ratio [OR], 1.2; 95% CI, 1.1-1.4), with CD (especially colonic disease location; P = 9.8E-09, OR, 1.7; 95% CI, 1.4-2.0), and in subjects who required surgery (both CD and UC; P = 3.6E-19, OR, 1.7; 95% CI, 1.5-1.9). Smoking increased risk of EIMs except for PSC, where there was a "protective" effect. Multiple serologic associations were observed, including with PSC (anti-nuclear cytoplasmic antibody; IgG and IgA, anti-Saccharomyces cerevisiae antibodies; and anti-flagellin) and any EIM (anti-nuclear cytoplasmic antibody; IgG and IgA, anti-Saccharomyces cerevisiae antibodies; and anti-Pseudomonas fluorescens-associated sequence). We identified genome-wide significant associations within major histocompatibility complex (ankylosing spondylitis and sacroiliitis, P = 1.4E-15; OR, 2.5; 95% CI, 2.0-3.1; PSC, P = 2.7E-10; OR, 2.8; 95% CI, 2.0-3.8; ocular, P = 2E-08, OR, 3.6; 95% CI, 2.3-5.6; and overall EIM, P = 8.4E-09; OR, 2.2; 95% CI, 1.7-2.9) and CPEB4 (skin, P = 2.7E-08; OR, 1.5; 95% CI, 1.3-1.8). Genetic associations implicated tumor necrosis factor, JAK-STAT, and IL6 as potential targets for EIMs. Contrary to previous reports, only 2% of our subjects had multiple EIMs and most co-occurrences were negatively correlated. CONCLUSIONS: We have identified demographic, clinical, and genetic associations with EIMs that revealed underlying mechanisms and implicated novel and existing drug targets-important steps toward a more personalized approach to IBD management.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Khrom M, Long M, Dube S, et al. Comprehensive Association Analyses of Extraintestinal Manifestations in Inflammatory Bowel Disease. Gastroenterology. 2024. PMID: 38490347. doi:10.1053/j.gastro.2024.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。